Full Text
Cost-Effectiveness Analysis of Tocilizumab Subcutaneous As First Line Biologic Monotherapy for Rheumatoid Arthritis Management In Greece

Abstract

Authors

K Athanasakis F Tarantilis A Skroumpelos J Kyriopoulos

Back to Volume 18, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×